Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: An alternative pathway to non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 154-164

  Wang, Yu Chien ^a   Lin, Ruo Kai ^a   Tan, Yi Hung ^a   Chen, Jung Ta ^a   Chen, Chih Yi ^a   Wang, Yi Ching ^a  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P53; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SEQUENCE ANALYSIS; WESTERN BLOTTING; WILD TYPE; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16644396297     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.139     Document Type: Article

References (35)

1. Oren M: Decision making by p53: Life, death and cancer. Cell Death Differ 10:431-442, 2003
2. Bennett WP, Hussain SP, Vahakangas KH, et al: Molecular epidemiology of human cancer risk: Gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 187:8-18, 1999
3. Midgley CA, Lane DP: p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189, 1997
4. Costa A, Marasca R, Valentinis B, et al: p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 176:45-53, 1995
5. Lowe SW, Sherr CJ: Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr Opin Genet Dev 13:77-83, 2003
6. Sharpless NE, DePinho RA. The INK4a/ARF locus and its two gene products. Curr Opin Genet Dev 9:22-30, 1999
7. Vonlanthen S, Heighway J, Tschan MP, et al: Expression of p16INK4a/p16-alpha and p19ARF/p16-beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 17:2779-2785, 1998
8. Xue Q, Sano T, Kashiwabara K, et al: Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. Pathol Int 52:103-109, 2002
9. Moll UM, Petrenko O: The MDM2-p53 interaction. Mol Cancer Res 1:1001-1008, 2003
10. Li M, Brooks CL, Wu-Baer F, et al: Mono-versus polyubiquitination: Differential control of p53 fate by Mdm2. Science 302:1972-1975, 2003
11. Koga T, Hashimoto S, Sugio K, et al: Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation, Int J Cancer 95:232-239, 2001
12. Eymin B, Gazzeri S, Brambilla C, et al: Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 21:2750-2761, 2002
13. Momand J, Jung D, Wilczynski S, et al: The MDM2 gene amplification database. Nucleic Acids Res 26:3453-3459, 1998
14. Ko JL, Cheng YW, Chang SL, et al: MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer, Int J Cancer 89:265-270, 2000
15. Higashiyama M, Doi O, Kodama K, et al: MDM2 gene amplification and expression in non-small-cell lung cancer: Immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 75:1302-1308, 1997
16. Dang J, Kuo ML, Eischen CM, et al: The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res 62:1222-1230, 2002
17. Brown DR, Thomas CA, Deb SP: The human oncoprotein MDM2 arrests the cell cycle: Elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 17:2513-2525, 1998
18. Bartel F, Taubert H, Harris LC: Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2:9-15, 2002
19. Sigalas I, Calvert AH, Anderson JJ, et al: Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nat Med 2:912-917, 1996
20. Evans SC, Viswanathan M, Grier JD, et al: An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20:4041-4049, 2001
21. Gottlieb TM, Leal JF, Seger R, et al: Crosstalk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis. Oncogene 21:1299-1303, 2002
22. Zhou BP, Liao Y, Xia W, et al: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3:973-982, 2001
23. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al: The INK4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723, 1998
24. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734, 1998
25. Wang YC, Chen CY, Chen SK, et al: High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Cancer Res 58:328-333, 1998
26. Pinyol M, Hernandez L, Martinez A, et al: INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 156:1987-1996, 2000
27. Lee SH, Kim HS, Park WS, et al: Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 110:587-592, 2002
28. Hsu HS, Wang YC, Tseng RC, et al: CpG island methylation is responsible for the p14AHF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer. Clin Cancer Res 10:4734-4741, 2004
29. Gazzeri S, Della Valle V, Chaussade L, et al: The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 58:3926-3931, 1998
30. Sano T, Hikino T, Xue Q, et al: Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma. Pathol Int 50:709-716, 2000
31. Fridman JS, Hernando E, Hemann MT, et al: Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 63:5703-5706, 2003
32. Onel K, Cordon-Cardo C: MDM2 and prognosis. Mol Cancer Res 2:1-8, 2004
33. Peterson EJ, Bogler O, Taylor SM: p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res 63:6579-6582, 2003
34. Mercer WE, Shields MT, Lin D, et al: Growth suppression induced by wild type p53 protein is accompanied by selective down regulation of proliferating cell nuclear antigen expression. Proc Natl Acad Sci U S A 88:1958-1962, 1991
35. Shivakumar CV, Brown DR, Deb S, et al: Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 15:6785-6793, 1995